CAS
APLS

Coppell Advisory Solutions’s Apellis Pharmaceuticals APLS Stock Holding History

Coppell Advisory Solutions’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,390
Closed -$1.95M – 45
2025
Q4 		$1.95M Buy
+77,390
New +$1.82M 0.19% 105
2025
Q1 		– Sell
-79
Closed -$2.52K – 412
2024
Q4 		$2.52K Hold
79
– – ﹤0.01% 1499
2024
Q3 		$2.33K Hold
79
– – ﹤0.01% 1420
2024
Q2 		$3.03K Buy
+79
New +$3.58K ﹤0.01% 1307
2023
Q4 		$4.73K Buy
+79
New +$4.01K ﹤0.01% 1110

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Coppell Advisory Solutions's APLS Position: Q1 2026 in Review

Coppell Advisory Solutions sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 77,390 shares — an estimated $1.95M sold.

Coppell Advisory Solutions first reported a position in APLS in Q4 2023 and held it in 5 quarters. The position peaked at $1.95M in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Coppell Advisory Solutions reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Coppell Advisory Solutions sold 77,390 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.95M.
  • Coppell Advisory Solutions first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Coppell Advisory Solutions's Apellis Pharmaceuticals position peaked at $1.95M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Coppell Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.